ClinicalTrials.Veeva

Menu

Qidong Hepatitis B Intervention Study

University of Oxford logo

University of Oxford

Status and phase

Completed
Phase 4

Conditions

Liver Neoplasms
Hepatitis B
Liver Diseases

Treatments

Biological: Hep-V Vax

Study type

Interventional

Funder types

Other

Identifiers

NCT00222664
Qidong-HBV-Study

Details and patient eligibility

About

During 1983-1990 in the Jiangsu province of China, 80,000 infants were randomised by area of birth between control, standard Hepatitis B vaccination (at 0, 1 and 6 months of age) and standard vaccination plus a booster dose at about 2 to 3 years of age. The aim is to prevent establishment of chronic HBV infection in early childhood, hence to prevent the morbidity of chronic hepatitis B in young adolescents and the incidence/mortality several decades later from liver cancer and other HBV related chronic liver diseases. Long-term follow-up through central registries will determine the impact of vaccination on liver cancer incidence and mortality.

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

all infants born in Qidong between September 1983 and November 1990

Exclusion criteria

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

3

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems